Harmony’s operating expenses include the following: Reconciliations of applicable GAAP financial measures to Non-GAAP financial measures are included at the end of this press release. Non-GAAP adjusted net income was $34.7 million, or $0.57 per diluted share, for the quarter ended June 30, 2022, compared to Non-GAAP adjusted net income of $21.9 million, or $0.37 per diluted share, for the same period in 2021. GAAP net income for the quarter ended June 30, 2022, was $23.5 million, or $0.39 per diluted share, compared to GAAP net income of $14.1 million, or $0.24 per diluted share, for the same period in 2021. The average number of patients on WAKIX increased to approximately 4,300 for the quarter ended June 30, 2022. The 45.0% growth versus the same period in 2021 is primarily attributed to strong commercial sales of WAKIX driven by continued organic demand. Net product revenues for the quarter ended Jwere $107.0 million, compared to $73.8 million for the same period in 2021. patients and will strengthen the partnership between Bioprojet and Harmony Biosciences,” said Professor Jean-Charles Schwartz, PhD, founder of Bioprojet. “Bioprojet is very excited about this transaction, which is designed to benefit U.S. If successful, these efforts could expand our franchise in narcolepsy by yielding one or more new products with the potential to launch during the WAKIX lifecycle.” market to develop innovative therapeutics based on pitolisant. “In addition, we are excited to announce our new agreement with Bioprojet, designed to leverage its drug discovery capabilities in combination with our proven commercial expertise in the U.S. Jacobs, President and Chief Executive Officer of Harmony. The second quarter represented our best quarter of performance in top line prescription demand in over two years,” stated John C. “Our continued momentum helped deliver another quarter of strong growth in both WAKIX ® net revenue and average number of patients on WAKIX. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company focused on delivering innovative therapies that improve the health of people living with rare neurological diseases, today reported financial results and business updates for the quarter ended June 30, 2022. 02, 2022 (GLOBE NEWSWIRE) - Harmony Biosciences Holdings, Inc. Phase 3 Idiopathic Hypersomnia (IH) INTUNE Study on Track with Site Activations and Patient EnrollmentĬonference Call and Webcast to be Held Today at 8:30 a.m. Signs New Agreement with Bioprojet Focused on Developing Innovative Therapeutics Based on Pitolisant, Expanding Harmony’s Opportunity in Narcolepsy the Same Period in 2021Īverage Number of Patients on WAKIX Increased to ~4,300 WAKIX ® (pitolisant) Net Revenue of $107.0 Million for Second Quarter 2022 Increase of 45% vs.

Cataplexy vs narcolepsy